Cecile Terrenoire Kai Wang Kelvin W Chan Tung Wendy K Chung Robert H Pass Jonathan T Lu Jyh-Chang Jean Amel Omari Kevin J Sampson Darrell N Kotton Gordon Keller Robert S Kass
10.1085/jgp.201210899
J Gen Physiol
2013 Jan;141(1):61-72.
CC BY-NC-SA
https://pubmed.ncbi.nlm.nih.gov/23277474/
Anti-Arrhythmia Agents / therapeutic use Ether-A-Go-Go Potassium Channels / genetics Long QT Syndrome / drug therapy Long QT Syndrome / genetics Mutation / genetics NAV1.5 Voltage-Gated Sodium Channel / genetics Pluripotent Stem Cells / physiology
Anti-Arrhythmia Agents / therapeutic use Ether-A-Go-Go Potassium Channels / genetics Long QT Syndrome / drug therapy Long QT Syndrome / genetics Mutation / genetics NAV1.5 Voltage-Gated Sodium Channel / genetics Pluripotent Stem Cells / physiology Case Reports Research Support, Non-U.S. Gov't Anti-Arrhythmia Agents / pharmacology Biophysical Phenomena Cell Communication Cells, Cultured ERG1 Potassium Channel Flecainide / pharmacology Flecainide / therapeutic use Humans Infant, Newborn Long QT Syndrome / pathology Male Mexiletine / pharmacology Mexiletine / therapeutic use Myocytes, Cardiac / drug effects Myocytes, Cardiac / pathology Pharmacogenetics Pluripotent Stem Cells / cytology Pluripotent Stem Cells / drug effects Sodium Channels / drug effects Sodium Channels / physiology Treatment Outcome Anti-Arrhythmia Agents ERG1 Potassium Channel Ether-A-Go-Go Potassium Channels KCNH2 protein, human NAV1.5 Voltage-Gated Sodium Channel SCN5A protein, human Sodium Channels Mexiletine Flecainide
PMC3536519
23277474
Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics
2013